With breast cancer on both sides of the family, a 29-year-old Utah attorney opted to reduce her own risk drastically.

The BRCA 14 nano-chip test, which is common in Israel, targets women of Ashkenazi and Ethiopian descent who have not been ...

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment ...

Hereditary breast cancer due to genetic mutations accounts for 5% to 10% of breast cancers. Breast cancer is the most ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

UAMS surgical oncologist Dr. Rhonda Henry Tillman says one of the most common questions she hears is rooted in that same fear.“One of the most common questions ...

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

A growing number of people are getting genetic testing for breast cancer, which has become more comprehensive and ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

In 2025, roughly two million people in the United States are expected to be diagnosed with some form of the disease.

Katharine Bisordi, a genetic counselor at Mercy Medical Center in Baltimore, said not everyone with CHEK2 will have the same ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...